These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9548447)

  • 1. Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma.
    Hanagiri T; Yoshino I; Takenoyama M; So T; Fujie H; Imabayashi S; Eifuku R; Yoshimatsu T; Osaki T; Nakanishi R; Ichiyoshi Y; Nagashima A; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1998 Feb; 89(2):192-8. PubMed ID: 9548447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells.
    Takenoyama M; Yoshino I; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1998 Jan; 89(1):60-6. PubMed ID: 9510477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients.
    Hanagiri T; Takenoyama M; Yoshimatsu T; Hirashima C; Yoshino I; Nakanishi K; Nagashima A; Nomoto K; Yasumoto K
    Cancer Immunol Immunother; 1996 Oct; 43(2):87-93. PubMed ID: 8954142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer.
    Yoshino I; Takenoyama M; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Ogami A; Yano K; Osaki T; Nakanishi R; Ichiyoshi Y; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1997 Aug; 88(8):743-9. PubMed ID: 9330606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
    Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
    Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
    Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
    Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
    Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
    Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
    Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
    Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
    Gohara R; Nakao M; Ogata Y; Isomoto H; Oizumi K; Itoh K
    Jpn J Cancer Res; 1997 Feb; 88(2):198-204. PubMed ID: 9119749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2.
    Chen YM; Ting CC; Peng JW; Yang WK; Yang KY; Tsai CM; Perng RP
    J Interferon Cytokine Res; 2000 Jan; 20(1):31-9. PubMed ID: 10670650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD3+CD56+CD8+ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients.
    Akagi J; Takai E; Tamori Y; Ogawa M
    Int J Oncol; 2001 Sep; 19(3):561-6. PubMed ID: 11494036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Roman JJ; Parham GP; Cannon MJ
    J Virol; 2000 May; 74(10):4729-37. PubMed ID: 10775611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor response of regional lymph node lymphocytes in human lung cancer.
    Takenoyama M; Yasumoto K; Harada M; Sugimachi K; Nomoto K
    Cancer Immunol Immunother; 1998 Dec; 47(4):213-20. PubMed ID: 9875674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1beta, IL-2, IL-4, and IL-6: possible involvement of dendritic cells.
    Saijo Y; Hong X; Tanaka M; Tazawa R; Liu SQ; Saijo K; Ohno T; Koike K; Ohkuda K; Satoh K; Nukiwa T
    Clin Cancer Res; 1999 May; 5(5):1203-9. PubMed ID: 10353758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.
    Matsuda M; Salazar F; Petersson M; Masucci G; Hansson J; Pisa P; Zhang QJ; Masucci MG; Kiessling R
    J Exp Med; 1994 Dec; 180(6):2371-6. PubMed ID: 7964510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo stimulation of tumor-draining lymph node cells from lung cancer patients: a potential resource for adoptive immunotherapy.
    Shan B; Li Q; He M; He Y
    Cell Mol Immunol; 2008 Aug; 5(4):307-13. PubMed ID: 18761819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
    Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
    Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
    Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K
    Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients.
    Chen YM; Yang WK; Whang-Peng J; Tsai WY; Hung YM; Yang DM; Lin WC; Perng RP; Ting CC
    J Immunother; 1997 Sep; 20(5):354-64. PubMed ID: 9336742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.